Straits Times Index
3,306.58 +3.39 (+0.10%) Nikkei
38,631.12 +395.05 (+1.03%) Hang Seng
18,496.45 -81.85 (-0.44%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,723.21 -370.10 (-0.58%) CMC Crypto 200
1,372.30 +59.67 (+4.55%)
CMPS May 2024 2.500 call
| Previous close | 6.00 |
| Open | 6.00 |
| Bid | 5.70 |
| Ask | 7.00 |
| Strike | 2.50 |
| Expiry date | 2024-05-17 |
| Day's range | 6.00 - 6.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
GlobeNewswireCompass Pathways to announce first quarter financial results on May 8, 2024
LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2024 ending March 31, 2024, and provide an update on recent business developments, on May 8, 2024. The management team will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2024. To access the call, please register in adva
- GlobeNewswire
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Mindful Health Solutions (MHS), one of the US’s leading providers of innovative behavioral health care, today announced that they have entered into a research collaboration agreement to inform the development of a scalable and cost-effective delivery model for COMP360 psilocybin treatment, if
- GlobeNewswire
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Journey Clinical, a leading psychedelic-assisted psychotherapy platform with the largest network of licensed therapists focused on psychedelics in the US, today announced they have entered into a research collaboration agreement to inform the development of a scalable and practical delivery
